A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer

Trial Profile

A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2018

At a glance

  • Drugs Defactinib (Primary) ; Paclitaxel (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Sponsors Verastem; Verastem Oncology
  • Most Recent Events

    • 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
    • 15 May 2017 Status changed from active, no longer recruiting to completed.
    • 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top